fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer – GSK

Written by | 31 Mar 2024

GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOTEN6/GOG3031/NSGO phase III… read more.

MHRA (UK) approves Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults – GSK

Written by | 11 Oct 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. It can… read more.

Dostarlimab effective in rectal cancer subset

Written by | 5 Jul 2022

PD-1 blockade with adjuvant dostarlimab in mismatch repair–deficient, locally advanced rectal cancer shows signs of high efficacy, researchers reported on June 5, 2022 in the NEJM/ New England… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.